Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE) (EDIPE)
Primary Purpose
Breast Cancer
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
myocardial perfusion SPECT
Sponsored by
About this trial
This is an interventional prevention trial for Breast Cancer focused on measuring Breast Cancer, Cardiac Toxicity, Deep Inspiration Breath Hold, Myocardial Perfusion Imaging
Eligibility Criteria
Inclusion Criteria:
- Patient with left sided breast cancer histologically confirmed after lumpectomy or mastectomy with/without lymph node involvement who are planned for DIBH-RT or IMRT
- Age > 18 years
- Karnofsky Performance Status (KPS) > 60%
- Absence of psychiatric illness hindering follow-up
- Patient understands French
- Signature of informed consent
- Patient registered with social security
Exclusion Criteria:
- Bilateral breast cancer
- History of thoracic irradiation
- Pregnancy or breastfeeding
- Any medical contraindication of cardiac SPECT or chest CT angiography.
- Any medical contraindication of Regadenoson
Sites / Locations
- Institut de cancérologie Strasbourg EuropeRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Patients with left sided breast cancer who are planned for
Arm Description
one of the following heart sparing techniques : DIBH radiotherapy IMRT
Outcomes
Primary Outcome Measures
Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy
Incidence of perfusion defects on follow-up myocardial perfusion SPECT scans
Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy
Incidence of perfusion defects on follow-up myocardial perfusion SPECT scans
Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy
Incidence of perfusion defects on follow-up myocardial perfusion SPECT scans
Secondary Outcome Measures
Assession of wall-motion abnormalities and left ventricular ejection fraction (LVEF) decrease
Incidence of left ventricular wall motion disorder and LVEF quantification on follow-up myocardial perfusion SPECT scans.
Assessing the relevance of mean heart dose in the prevention of Radiation-induced heart disease (RIHD) compared to cardiac substructures.
Measurement of the doses delivered to the cardiac volumes and its substructures.
Influence of cardiac risk factors on post-radiation myocardial perfusion.
Influence of anticancer therapy exposure on post-radiation myocardial perfusion
Anticancer therapy characteristics (type)
Influence of anticancer therapy exposure on post-radiation myocardial perfusion
Anticancer therapy characteristics (dose)
Influence of anticancer therapy exposure on post-radiation myocardial perfusion
Anticancer therapy characteristics (duration)
Impact of the location of the tumor bed boost on the cardiac dose.
Location of the tumor bed boost
Impact of the location of the tumor bed boost on the cardiac dose.
Cardiac dose
Full Information
NCT ID
NCT05454553
First Posted
June 22, 2022
Last Updated
November 23, 2022
Sponsor
Institut de cancérologie Strasbourg Europe
1. Study Identification
Unique Protocol Identification Number
NCT05454553
Brief Title
Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE)
Acronym
EDIPE
Official Title
Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE)
Study Type
Interventional
2. Study Status
Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 27, 2022 (Actual)
Primary Completion Date
October 27, 2024 (Anticipated)
Study Completion Date
October 27, 2024 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Institut de cancérologie Strasbourg Europe
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Breast irradiation is known to cause radiation-induced heart disease (RIHD) many years later after radiotherapy. Recent studies suggest that RIHD could be an earlier complication and that subclinical cardiac injury can be detected such as myocardial perfusion defects. Myocardial perfusion single photon emission computed tomography (SPECT) is a sensitive and specific technique able to detect perfusion abnormalities which are more frequent in left-sided breast cancer patients because of the cardiac exposure.
The most used technique for breast cancer irradiation is tangential opposed field, but this technique exposes the left anterior descending coronary artery to high dose during left breast irradiation.
There are different cardiac sparing techniques to reduce heart exposure such as:
Deep inspiration breath-hold (DIBH) which displaces the heart out of the radiation beam
Intensity-modulated radiation therapy (IMRT) which decreases heart exposure to high doses but changes the dose distribution in the heart and increases lower doses.
Detailed Description
In breast radiotherapy, especially for left sides breast cancers, the heart is the organ-at-risk which whose dose constraints are source of controversies. Historically breast cancer radiation therapy was associated with a significantly increased cardiac mortality. Two meta-analyses founded that the cardiac mortality risk was increased by 27% to 38%. This result is linked to outdated 2-D treatment techniques causing massive cardiac overexposure (Clarke M et al. 2005, Cheng YJ et al. 2017).
Three dimensional conformational radiotherapy reduced mean heart dose but the link between heart irradiation and radiation-induced heart damages doesn't seem to have threshold therefore to RHID is still a matter of concern (Darby SC et al. 2013; Taylor C et al. 2017).
The most used technique for breast cancer irradiation is opposite tangential field radiotherapy, however, it exposes the anterior interventricular coronary artery to a high dose during left breast irradiation (Nieder C et al. 2007). Therefore, radiotherapy techniques have developed to reduce cardiac exposure such as deep inspiration breath hold (DBIH) and intensity modulated radiation therapy (IMRT).
DBIH "mechanically" moves the heart away from the radiation beam and IMRT the dose distribution in the heart and reduces its exposure to high doses (Boda-Heggemann J et al. 2016, Lauche O et al. 2016).
Nevertheless, recent studies suggest that even with this level of cardiac exposure subclinical cardiac alterations may be detected, such as myocardial perfusion deficit (Eber et al. 2022; Marks LB et al. 2005; Gyenes G et al. 1997; Sioka C et al. 2011; Seddon B et al. 2002; Eftekhari M et al. 2015).
The heart is a complex and heterogeneous organ, however it's mostly considered as an homogeneous organ-at-risk during treatment planning in daily practice. Dosimetric optimization is therefore mainly performed on the global cardiac structure and the mean cardiac dose (MHD). Dosimetric studies reported a poor correlation between MHD and mean doses to cardiac substructures questioning the relevance of the MHD as a reflection of the dose distribution to the heart (Jacob S et al. 2016).
Recent data suggested to take account of the histological diversity and the functional complexity of the cardiac substructure (Darby SC et al. 2010; Gillette EL et al. 1985; Ghita M et al. 2020; Eber J et al. 2021). This delineation is not performed in routine clinical practice due to the poorly reproducible and time-consuming manual contouring.
The development of auto-segmentation software can save time and improve the quality of the delineation process of these substructures in order to optimize dosimetry (Feng M et al. 2011; Maffei N et al. 2020).
The investigators propose a single-centre prospective study to evaluate the utility of deep inspiration breath hold using a surface monitoring technique (AlignRT, Vision RT Ltd., London, UK) and IMRT, as means to prevent the development of myocardial perfusional deficits in patients treated for left breast cancer, using stress and, if necessary, resting myocardial scintigraphy.
Before initiation of radiotherapy patients will performed a chest CT scan in the treatment position for 3D treatment planning and dose calculation; a chest CT angiography for delineation of cardiac substructures; and a myocardial perfusion SPECT imaging to provide a map of regional myocardial perfusion and determine left ventricle ejection fraction (LVEF).
Treatment phase will consist of the standard course of breast radiotherapy in our department. The main difference will be in the delineation of the organ at risk, cardiac substructures will be delineated to obtain the dosimetry During the follow up period, patient will be scheduled to undergo cardiac SPECT before and at 3-, 6-, and 12-month period post irradiation. Stress ECG-gated SPECT will be performed after infusion of 3 MBq/kg 99mTc-tetrofosmin (Myoview®, General Electrics Healthcare) at peak pharmacological stress with regadenoson, (single dosage: 400 µg; Rapiscan®, GE healthcare)
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer
Keywords
Breast Cancer, Cardiac Toxicity, Deep Inspiration Breath Hold, Myocardial Perfusion Imaging
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
58 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Patients with left sided breast cancer who are planned for
Arm Type
Experimental
Arm Description
one of the following heart sparing techniques :
DIBH radiotherapy
IMRT
Intervention Type
Other
Intervention Name(s)
myocardial perfusion SPECT
Intervention Description
For all participants, myocardial perfusion SPECT will be performed :
at 3, 6 and 12 months (post irradiation)
Primary Outcome Measure Information:
Title
Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy
Description
Incidence of perfusion defects on follow-up myocardial perfusion SPECT scans
Time Frame
at 3 months from the end of radiotherapy
Title
Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy
Description
Incidence of perfusion defects on follow-up myocardial perfusion SPECT scans
Time Frame
at 6 months from the end of radiotherapy
Title
Evaluation of DIBH and IMRT efficacy in preventing perfusion defect for left-sided breast cancer after radiotherapy
Description
Incidence of perfusion defects on follow-up myocardial perfusion SPECT scans
Time Frame
at 12 months from the end of radiotherapy
Secondary Outcome Measure Information:
Title
Assession of wall-motion abnormalities and left ventricular ejection fraction (LVEF) decrease
Description
Incidence of left ventricular wall motion disorder and LVEF quantification on follow-up myocardial perfusion SPECT scans.
Time Frame
up to 12 months from the end of radiotherapy
Title
Assessing the relevance of mean heart dose in the prevention of Radiation-induced heart disease (RIHD) compared to cardiac substructures.
Description
Measurement of the doses delivered to the cardiac volumes and its substructures.
Time Frame
up to 12 months from the end of radiotherapy
Title
Influence of cardiac risk factors on post-radiation myocardial perfusion.
Time Frame
up to 12 months from the end of radiotherapy
Title
Influence of anticancer therapy exposure on post-radiation myocardial perfusion
Description
Anticancer therapy characteristics (type)
Time Frame
up to 12 months from the end of radiotherapy
Title
Influence of anticancer therapy exposure on post-radiation myocardial perfusion
Description
Anticancer therapy characteristics (dose)
Time Frame
up to 12 months from the end of radiotherapy
Title
Influence of anticancer therapy exposure on post-radiation myocardial perfusion
Description
Anticancer therapy characteristics (duration)
Time Frame
up to 12 months from the end of radiotherapy
Title
Impact of the location of the tumor bed boost on the cardiac dose.
Description
Location of the tumor bed boost
Time Frame
up to 12 months from the end of radiotherapy
Title
Impact of the location of the tumor bed boost on the cardiac dose.
Description
Cardiac dose
Time Frame
up to 12 months from the end of radiotherapy
10. Eligibility
Sex
Female
Gender Based
Yes
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with left sided breast cancer histologically confirmed after lumpectomy or mastectomy with/without lymph node involvement who are planned for DIBH-RT or IMRT
Age > 18 years
Karnofsky Performance Status (KPS) > 60%
Absence of psychiatric illness hindering follow-up
Patient understands French
Signature of informed consent
Patient registered with social security
Exclusion Criteria:
Bilateral breast cancer
History of thoracic irradiation
Pregnancy or breastfeeding
Any medical contraindication of cardiac SPECT or chest CT angiography.
Any medical contraindication of Regadenoson
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Valérie SARTORI
Phone
368767223
Ext
33
Email
v.sartori@icans.eu
First Name & Middle Initial & Last Name or Official Title & Degree
Manon VOEGELIN
Phone
368339523
Ext
33
Email
promotion-rc@icans.eu
Facility Information:
Facility Name
Institut de cancérologie Strasbourg Europe
City
Strasbourg
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manon VOEGELIN
Email
promotion-rc@icans.eu
First Name & Middle Initial & Last Name & Degree
Martin SCHMITT, MD
12. IPD Sharing Statement
Citations:
PubMed Identifier
16360786
Citation
Clarke M, Collins R, Darby S, Davies C, Elphinstone P, Evans V, Godwin J, Gray R, Hicks C, James S, MacKinnon E, McGale P, McHugh T, Peto R, Taylor C, Wang Y; Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 Dec 17;366(9503):2087-106. doi: 10.1016/S0140-6736(05)67887-7.
Results Reference
background
PubMed Identifier
28529208
Citation
Cheng YJ, Nie XY, Ji CC, Lin XX, Liu LJ, Chen XM, Yao H, Wu SH. Long-Term Cardiovascular Risk After Radiotherapy in Women With Breast Cancer. J Am Heart Assoc. 2017 May 21;6(5):e005633. doi: 10.1161/JAHA.117.005633.
Results Reference
background
PubMed Identifier
23484825
Citation
Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Bronnum D, Correa C, Cutter D, Gagliardi G, Gigante B, Jensen MB, Nisbet A, Peto R, Rahimi K, Taylor C, Hall P. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013 Mar 14;368(11):987-98. doi: 10.1056/NEJMoa1209825.
Results Reference
background
PubMed Identifier
28319436
Citation
Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, Dodwell D, Ewertz M, Gray R, Jagsi R, Pierce L, Pritchard KI, Swain S, Wang Z, Wang Y, Whelan T, Peto R, McGale P; Early Breast Cancer Trialists' Collaborative Group. Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol. 2017 May 20;35(15):1641-1649. doi: 10.1200/JCO.2016.72.0722. Epub 2017 Mar 20.
Results Reference
background
PubMed Identifier
17547777
Citation
Nieder C, Schill S, Kneschaurek P, Molls M. Influence of different treatment techniques on radiation dose to the LAD coronary artery. Radiat Oncol. 2007 Jun 5;2:20. doi: 10.1186/1748-717X-2-20.
Results Reference
background
PubMed Identifier
26867877
Citation
Boda-Heggemann J, Knopf AC, Simeonova-Chergou A, Wertz H, Stieler F, Jahnke A, Jahnke L, Fleckenstein J, Vogel L, Arns A, Blessing M, Wenz F, Lohr F. Deep Inspiration Breath Hold-Based Radiation Therapy: A Clinical Review. Int J Radiat Oncol Biol Phys. 2016 Mar 1;94(3):478-92. doi: 10.1016/j.ijrobp.2015.11.049. Epub 2015 Dec 17.
Results Reference
background
PubMed Identifier
27648167
Citation
Lauche O, Kirova YM, Fenoglietto P, Costa E, Lemanski C, Bourgier C, Riou O, Tiberi D, Campana F, Fourquet A, Azria D. Helical tomotherapy and volumetric modulated arc therapy: New therapeutic arms in the breast cancer radiotherapy. World J Radiol. 2016 Aug 28;8(8):735-42. doi: 10.4329/wjr.v8.i8.735.
Results Reference
background
PubMed Identifier
35165015
Citation
Eber J, Leroy-Freschini B, Antoni D, Noel G, Pflumio C. Increased cardiac uptake of (18F)-fluorodeoxyglucose incidentally detected on positron emission tomography after left breast irradiation: How to interpret? Cancer Radiother. 2022 Sep;26(5):724-729. doi: 10.1016/j.canrad.2021.10.010. Epub 2022 Feb 12.
Results Reference
background
PubMed Identifier
16111592
Citation
Marks LB, Yu X, Prosnitz RG, Zhou SM, Hardenbergh PH, Blazing M, Hollis D, Lind P, Tisch A, Wong TZ, Borges-Neto S. The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):214-23. doi: 10.1016/j.ijrobp.2005.01.029.
Results Reference
background
PubMed Identifier
9143466
Citation
Gyenes G, Fornander T, Carlens P, Glas U, Rutqvist LE. Detection of radiation-induced myocardial damage by technetium-99m sestamibi scintigraphy. Eur J Nucl Med. 1997 Mar;24(3):286-92. doi: 10.1007/BF01728765.
Results Reference
background
PubMed Identifier
22067743
Citation
Sioka C, Exarchopoulos T, Tasiou I, Tzima E, Fotou N, Capizzello A, Ragos V, Tsekeris P, Fotopoulos A. Myocardial perfusion imaging with (99 m)Tc-tetrofosmin SPECT in breast cancer patients that received postoperative radiotherapy: a case-control study. Radiat Oncol. 2011 Nov 8;6:151. doi: 10.1186/1748-717X-6-151.
Results Reference
background
PubMed Identifier
12208576
Citation
Seddon B, Cook A, Gothard L, Salmon E, Latus K, Underwood SR, Yarnold J. Detection of defects in myocardial perfusion imaging in patients with early breast cancer treated with radiotherapy. Radiother Oncol. 2002 Jul;64(1):53-63. doi: 10.1016/s0167-8140(02)00133-0.
Results Reference
background
PubMed Identifier
27408875
Citation
Eftekhari M, Anbiaei R, Zamani H, Fallahi B, Beiki D, Ameri A, Emami-Ardekani A, Fard-Esfahani A, Gholamrezanezhad A, Seid Ratki KR, Roknabadi AM. Radiation-induced myocardial perfusion abnormalities in breast cancer patients following external beam radiation therapy. Asia Ocean J Nucl Med Biol. 2015 Winter;3(1):3-9.
Results Reference
background
PubMed Identifier
27056179
Citation
Jacob S, Pathak A, Franck D, Latorzeff I, Jimenez G, Fondard O, Lapeyre M, Colombier D, Bruguiere E, Lairez O, Fontenel B, Milliat F, Tamarat R, Broggio D, Derreumaux S, Ducassou M, Ferrieres J, Laurier D, Benderitter M, Bernier MO. Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study. Radiat Oncol. 2016 Apr 7;11:54. doi: 10.1186/s13014-016-0627-5.
Results Reference
background
PubMed Identifier
20159360
Citation
Darby SC, Cutter DJ, Boerma M, Constine LS, Fajardo LF, Kodama K, Mabuchi K, Marks LB, Mettler FA, Pierce LJ, Trott KR, Yeh ET, Shore RE. Radiation-related heart disease: current knowledge and future prospects. Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):656-65. doi: 10.1016/j.ijrobp.2009.09.064.
Results Reference
background
PubMed Identifier
4066441
Citation
Gillette EL, McChesney SL, Hoopes PJ. Isoeffect curves for radiation-induced cardiomyopathy in the dog. Int J Radiat Oncol Biol Phys. 1985 Dec;11(12):2091-7. doi: 10.1016/0360-3016(85)90089-6.
Results Reference
background
PubMed Identifier
32663535
Citation
Ghita M, Gill EK, Walls GM, Edgar KS, McMahon SJ, Osorio EV, Bergom C, Grieve DJ, Watson CJ, McWilliam A, Aznar M, van Herk M, Williams KJ, Butterworth KT. Cardiac sub-volume targeting demonstrates regional radiosensitivity in the mouse heart. Radiother Oncol. 2020 Nov;152:216-221. doi: 10.1016/j.radonc.2020.07.016. Epub 2020 Jul 12.
Results Reference
background
PubMed Identifier
34728116
Citation
Eber J, Nannini S, Chambrelant I, Le Fevre C, Noel G, Antoni D. [Impact of thoracic irradiation on cardiac structures]. Cancer Radiother. 2022 May;26(3):526-536. doi: 10.1016/j.canrad.2021.08.022. Epub 2021 Oct 30. French.
Results Reference
background
PubMed Identifier
20421148
Citation
Feng M, Moran JM, Koelling T, Chughtai A, Chan JL, Freedman L, Hayman JA, Jagsi R, Jolly S, Larouere J, Soriano J, Marsh R, Pierce LJ. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):10-8. doi: 10.1016/j.ijrobp.2009.10.058. Epub 2010 Apr 24.
Results Reference
background
PubMed Identifier
31835189
Citation
Maffei N, Fiorini L, Aluisio G, D'Angelo E, Ferrazza P, Vanoni V, Lohr F, Meduri B, Guidi G. Hierarchical clustering applied to automatic atlas based segmentation of 25 cardiac sub-structures. Phys Med. 2020 Jan;69:70-80. doi: 10.1016/j.ejmp.2019.12.001. Epub 2019 Dec 10.
Results Reference
background
Learn more about this trial
Efficacity of Deep Inspiration Breath Hold and Intensity-modulated Radiotherapy in Preventing PErfusion Defect for Left Sided Breast Cancer (EDIPE)
We'll reach out to this number within 24 hrs